Supports pragmatic clinical trials testing cancer-related interventions across the cancer control continuum, using a UG3/UH3 phased cooperative agreement to refine the intervention (UG3) and conduct the trial (UH3) in real-world U.S. settings, with milestone-based transition.
Eligibility criteria:
-
Eligible applicants include U.S. higher education institutions, nonprofits, for-profits, and eligible governments; foreign organizations are not eligible, but foreign components are allowed.
-
PD/PI(s) with the skills and resources to carry out the project; Multiple PDs/PIs permitted.
-
Clinical trial required with at least one intervention and one control/comparison condition; pragmatic design expected.
-
Required registrations: SAM (UEI), eRA Commons, Grants.gov.
-
Applicant organizations may submit multiple scientifically distinct applications.
Funding details:
-
Mechanism: UG3/UH3 cooperative agreement.
-
Budget: up to $500,000 direct costs per year (UG3); up to $750,000 direct costs per year (UH3).
-
Project period: up to 2 years (UG3) + up to 4 years (UH3).
Deadline:
-
Application due date: Oct 17, 2025.
-
FOA expires: Nov 18, 2025.
-
All applications due by 5:00 PM local time.
Where to go for further information:
-
Scientific inquiries: [email protected].